A new candy coated chewable form of ADHD medication designed to be marketed towards young children is getting ready to hit the market. The drug, Adzenys XR-ODT is being manufactured by Dallas based pharmaceutical company Neos Therapeutics is slated to be released just in time for children coming back to school in the Fall of 2016. The drug is being hailed as an orally disintegrating alternative to the controversial Adderall XR.
The company has already hired 125 sales agents who are actively engaging with US based healthcare professionals on how to launch the product effectively. The CEO of Neos Therapeutics, Vipin K. Garg had the following giddy announcement ahead of the company’s 2016 Q1 earnings conference call to investors:
“We look forward to offering patients, their parents and caregivers with this new treatment options ahead of the back-to-school season this summer and expanding our focus into newly diagnosed pediatric patients and adolescent and adult patients.”
It is quite disturbing this new trend of pharmaceutical companies rolling out new drugs designed to cater exclusively towards younger and younger audiences. The FDA just recently approved the use of Oxycontin to manage pain in children 11-16 years old. They seem to be part and parcel to this global scheme to drug all of society under the guise of various psychiatric disorders. The overdiagnosis of ADHD in children is an appalling injustice that is increasingly being used as a reason to keep children more manageable and docile instead of simple parenting and guidance.
Current figures estimate that around 75 percent of children diagnosed with ADHD are placed on these powerful amphetamine based medications which work on the central nervous system to regulate the area of the brain responsible for impulse control. It seems lawmakers and the FDA are in dire need of this medication then, because they seem to have littler reservations in the way recommending these meds when it comes to both our children and adults. Children who are prescribed these meds usually continue taking them all the way into adulthood and it becomes increasingly debilitating the older they get. The need to increase dosing quickly becomes apparent and this has its own set of complications.
There is virtually no need to make this drug more accessible and palatable to a child. Flintstones gummy bear vitamins were one thing but this is a completely different can of worms ready to be unleashed. The rolling out of this new drug has largely been ignored, or met with flippant responses from many established professionals in the field of healthcare. One notable professor of psychiatry from the University of Michigan’s C.S. Mott Children’s Hospital met the new publicity behind the drug with understandable cynicism.
“There’s nothing revolutionary about this drug,” Biermann said. “It’s simply another delivery mechanism for a medication that already exists and has widespread use.”
The more we continue to rely on these powerful medications to treat more serious underlying psychological disorders we set a dangerous precedent for society as a whole. It is easy to prescribe medication but far more tedious and unnerving to get to the root of the problem affecting that person. Often it is a range of factors that play a part in a child or adult suffering from ADHD and there needs to be a more comprehensive approach to identifying these symptoms and alternative, more holistic ways in addressing them.